By selecting the Yes option, leaving Amgen.eu option you understand that you are leaving the corporate page of Amgen Europe and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen is committed to developing new therapies to treat serious illnesses. The process that brings a new drug from the research laboratory to the marketplace is a long and careful one. One of the most important steps in the development process is the clinical trial, which is a study with people who volunteer to receive the drug and be observed for its effects. It is through these trials that investigational drugs are tested to determine whether they can benefit human beings.
Whether or not you qualify for a clinical trial depends on a number of factors, including your medical condition. Your physician will discuss these factors with you and provide comprehensive information on the investigational drug and the trial itself.
AmgenTrials.com is dedicated to bringing information about Amgen's clinical trials to patients and healthcare communities. Content reflected on AmgenTrials.com is currently updated on a weekly basis. For the latest updated information concerning Amgen clinical trials in Europe, please refer to https://eudract.ema.europa.eu/